Clinical Trials Logo

Vertigo, Peripheral clinical trials

View clinical trials related to Vertigo, Peripheral.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04687371 Completed - Vestibular Disease Clinical Trials

The Effect of Proprioseptive Vestibular Rehabilitation in Patients With Peripheral Vestibular Hypofunction

Start date: February 10, 2021
Phase: N/A
Study type: Interventional

The aim of this study was to investigate the effect of proprioceptive vestibular rehabilitation on balance, functional mobility, posture, sensory profile and quality of life in patients with vertigo due to peripheral vestibular hypofunction.

NCT ID: NCT04268745 Completed - Fall Clinical Trials

Virtual Environments for Vestibular Rehabilitation

Start date: August 21, 2019
Phase: N/A
Study type: Interventional

The specific aims of this pilot project are: Aim #1: Determine the extent to which sensory integration strategies differ between 28 individuals with unilateral vestibular hypofunction and 28 age-matched peers. Participants' postural sway will be recorded as they experience two levels of moving stars10 and white noise, while standing on the floor or a compliant surface. Our working hypothesis is that patients with vestibular hypofunction utilize substitution strategies such that they will demonstrate greater visual and auditory reliance compared with controls, particularly when somatosensory cues are reduced via the support surface. We will then explore whether these mechanism changes after training. Aim #2: Develop the protocol and establish the feasibility of a randomized controlled trial (RCT) comparing C.S.I. training to standard vestibular rehabilitation. Following the assessment, the 28 patients will be randomized into standard vestibular rehabilitation vs. C.S.I. training. This pilot study will enable us to test the feasibility of our recruitment, randomization procedures, establish attrition rate, and test the training protocol. Aim #3: Generate pilot data for sample size calculation for a properly powered RCT. The follow up RCT will test the effect of C.S.I. training on: Visual Vertigo Analog Scale (VVAS), Functional Gait Analysis (primary); balance confidence, overall disability (descriptive). In our preliminary study, 8 patients met the inclusion criteria for the current proposal. Following the C.S.I. training, they had a large effect size of 1.17 on the VVAS. The current study will allow us to identify the between-group effect size for the VVAS and for a functional gait outcome.

NCT ID: NCT04070664 Completed - Oxidative Stress Clinical Trials

Thiol/Disulphide Homeostasis and Albumin in Vertigo

Start date: July 1, 2018
Phase:
Study type: Observational

Vertigo is a common complaint in the Emergency Department (ED). The differential diagnosis of central and peripheral vertigo is a difficult issue that directly affects mortality. Magnetic resonance imaging (MRI) is the preferred diagnostic tool, but may not be suitable in all patients due to logistic and economic conditions. In this study, the investigators evaluated the role of thiol/disulfide homeostasis (TDH) parameters and ischemia modified albumin (IMA) levels to assist in the value of being used instead of MRI.

NCT ID: NCT03974464 Completed - Vertigo, Peripheral Clinical Trials

Copeptin and the S-100b Protein in Stroke

Start date: May 1, 2016
Phase:
Study type: Observational

This study evaluated the value of using copetin and protein S 100 b to eliminate the diagnosis of stroke in patients presenting with vertigo in emergency departments. All patients benefited from the S 100b protein assay, copeptin and brain MRI.

NCT ID: NCT02112578 Completed - Vertigo, Peripheral Clinical Trials

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

Start date: November 1, 2016
Phase: Phase 3
Study type: Interventional

- Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate) to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of treatment; - Evaluation of impact on quality of life in vertigo; - Compare the intensity of daytime sleepiness in the two treatment groups; - Compare the efficacy of drugs in relieving each of the 10 symptoms that make up the VS; - Compare the duration of treatment in both treatment groups; - Compare Adehence; - Compare the level of satisfaction from each group from the investigators and the subjects; - Adverse events;